Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )

Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies

This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.

Studieöversikt

Detaljerad beskrivning

This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.

Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.

Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.

Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.

Studietyp

Observationell

Inskrivning (Beräknad)

60

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300020
        • National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.

Beskrivning

Inclusion Criteria

  1. age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
  2. gender: no gender limit;
  3. sibling identical hematopoietic stem cell transplantation;
  4. fair general status, ECOG score <2 points;
  5. no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.

Exclusion Criteria:

  1. uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
  2. pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
  3. psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
  4. known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
  5. history of tumor and treatment for any tumor within the past 3 years;
  6. Prior hematopoietic stem cell transplantation;
  7. Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
  8. Subjects considered unsuitable for enrollment by the investigator.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
p-ALG cohort

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of acute graft-versus-host disease (aGVHD)
Tidsram: within 100 days after hematopoietic stem cell infusion

aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria.

within 100 days after hematopoietic stem cell infusion
Incidence of chronic graft-versus-host disease (cGVHD)
Tidsram: 5 years after hematopoietic stem cell transplantation

cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines

5 years after hematopoietic stem cell transplantation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
1-year implantation rate
Tidsram: 1-year

The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year

1-year
Overall survival rate
Tidsram: 5 years after hematopoietic stem cell transplantation

All-cause mortality from hematopoietic stem cell infusion to the last follow-up

5 years after hematopoietic stem cell transplantation
Rejection (AA) or recurrence (malignant)
Tidsram: 5 years after hematopoietic stem cell transplantation

Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up

5 years after hematopoietic stem cell transplantation
Incidence of fungal infection
Tidsram: 2 years after hematopoietic stem cell infusion

Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Incidence of cytomegalovirus infection
Tidsram: 2 years after hematopoietic stem cell infusion

Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Incidence of Epstein-Barr virus infection
Tidsram: 2 years after hematopoietic stem cell infusion

Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Transplant-related mortality
Tidsram: 5 years after hematopoietic stem cell infusion

Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion

5 years after hematopoietic stem cell infusion
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Tidsram: 2 years after hematopoietic stem cell infusion

Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

30 november 2026

Primärt slutförande (Beräknad)

31 augusti 2028

Avslutad studie (Beräknad)

31 augusti 2028

Studieregistreringsdatum

Först inskickad

2 november 2026

Först inskickad som uppfyllde QC-kriterierna

11 november 2026

Första postat (Faktisk)

17 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera